The Immune Disease Institute advances the public welfare by transferring its discoveries and inventions to the commercial market where they can be developed into new drugs, therapies, and biomedical devices. Licensing fees and royalty income from technology transfer can be reinvested in IDI research leading to yet additional discoveries. Thus, public investments in basic research are repaid many-fold through improvements in medical care.
The Office of Technology Development (OTD) administers this critical activity. OTD manages the patenting of intellectual property, assesses the commercial potential of IDI technology, and markets candidate technologies. The office negotiates and manages contracts for the transfer of materials between our investigators and their collaborators from academia and industry, inter-institutional and industry partnerships, and technology licensing. For additional detail and Institute policies on intellectual property, please visit How OTD works.
Licensing opportunities at IDI are divided into patented technologies and research tools.